This article has Open Peer Review reports available.
Spontaneous intracranial hemorrhage as an initial manifestation of primary Sjögren’s syndrome: a case report
© Wang and Zhang; licensee BioMed Central Ltd. 2013
Received: 28 February 2013
Accepted: 26 July 2013
Published: 29 July 2013
Sjögren’s syndrome can involve the central nervous system; however, spontaneous intracranial hemorrhage has rarely been reported as the initial manifestation.
We report a 39-year-old woman with primary Sjögren’s syndrome presenting with intracranial hemorrhage. The diagnosis of primary Sjögren’s syndrome was based on the presence of ocular dryness, salivary gland secretory and excretory dysfunction confirmed with dynamic tracer emission CT, and positive anti-Sjögren’s syndrome A and anti-Sjögren’s syndrome B antibodies.
Primary Sjögren’s syndrome can present with variable central nervous system signs, which may precede the classic sicca symptoms. Therefore, Sjögren’s syndrome-associated indicators should be investigated in patients without the common risk factors for stroke who present with spontaneous intracranial hemorrhage.
Sjögren’s syndrome (SS) is a common autoimmune disease. The histopathological hallmark is periductal lymphocytic infiltration of the exocrine glands, mainly the salivary and lacrimal glands, which results in loss of secretory function. The annual incidence has been estimated at 3.9–6.0 per 100,000 population [1, 2]. SS has a marked female preponderance with a female-to-male ratio of 13:1. It also features a later age at onset, with a median age of 54 years for women and 58 years for men at the first diagnosis . This syndrome is classified as primary SS (pSS) in the absence of other autoimmune diseases, and as secondary SS when it is associated with other autoimmune diseases such as rheumatoid arthritis, scleroderma, systemic lupus erythematosus, AIDS, hepatitis C infection, pre-existing lymphoma sarcoidosis, graft-versus-host disease, or the use of anticholinergic drugs.
The neurological manifestations of pSS involve both the peripheral and central nervous systems. Peripheral nervous system involvement is considered the most common neurological manifestation in pSS, and is characterized by predominantly sensory or occasionally mixed neuropathies, and mononeuritis multiplex. Central nervous system involvement occurs in 5.8–68% of pSS patients [4, 5] and, in most cases, neurological manifestations precede the sicca symptoms . Central nervous system lesions in pSS vary from diffuse involvement, which manifests as cognitive deficits or meningoencephalitis, to focal involvement, which presents with similar symptoms to multiple sclerosis or neuromyelitis optica . SS-associated infarction seldom occurs with stroke-like features such as aphasia or hemiplegia  and SS is even more rarely complicated with severe cerebral artery lesions, particularly hemorrhagic stroke. We report a case of a patient with pSS who presented with intracranial hemorrhage (ICH).
All of the additional examination results were normal, including ambulatory blood pressure and electrocardiogram; chest CT; cardiac ultrasonography; and examinations of the digestive, urinary, and uterine systems, and the breasts and appendages. Vision in the left and right eyes was 0.6 and 0.5, respectively. Schirmer’s tear test results in both eyes were <2 mm in 5 min (normal >15 mm); tear breakup time was 2 s (normal ≥10 s); and punctate fluorescein staining was >10 (normal <10).
The results of routine laboratory studies were also at normal levels, including complete blood cell count, coagulation, liver function, kidney and thyroid, lipids, glucose, glycosylated hemoglobin, C-reactive protein, and anti-O chain. Serological tests for HBsAg, hepatitis C virus, human immunodeficiency virus, syphilis, and tumor markers were negative. Erythrocyte sedimentation rate (ESR) was 62 mm/1st h; rheumatoid factor, 701 IU/mL (normal <25); antibody SS-A titer, 95 ng/mL; SS-B, 58 ng/mL; and recombinant Ro-52, 83 ng/mL (normal <10). Immunoglobulin (Ig) G was 18.7 g/L (normal 6–16); IgA, 6.86 g/L (normal, 0.4–3.3); IgM, 2.14 g/L (normal, 0.4–2.6); complement C3, 0.44 g/L (normal, 0.85–1.93); and C4, 0.13 g/L (normal, 0.12–0.36). Other auto-antibodies, including anti-β2-glycoprotein-I, anti-cardiolipin, anti-TB, and paraneoplastic antibody (anti-Hu, Yo, Ri, NMDA) were negative.
Based on the abnormal laboratory findings, the patient was diagnosed with pSS-associated cerebral vasculitis with ICH extending into the ventricular system, and with occlusion of the terminal portion of the left internal carotid artery accompanied by moyamoya vessels (quasi-moyamoya disease), as well as with multiple lacunar infarctions.
After the diagnosis, methylprednisolone 160 mg/day was administered by intravenous injection for 1 week, with oral leflunomide 10 mg/day. Follow-up CT was performed 2 weeks after admission and revealed that the hemorrhage was completely absorbed with no evidence of hydrocephalus; therefore the patient was discharged. At the 3-month follow-up, the patient was completely independent, with no discomfort, and normal physical examination findings. Laboratory tests showed positive results for SS-A/SS-B/Re-52 antibodies, and elevated rheumatoid factor, but all of the titers were lower than that of the initial results.
Only five case of pSS-associated ICH have been reported [8–12]. Unlike our case, all of the five reported cases had a clear history of pSS prior to the ICH, and none had ICH as the first manifestation of pSS. Four patients developed aneurysms leading to subarachnoid hemorrhage [9–12].
Currently, vasculitis is a recognized feature of SS and is the pathological basis of the nervous system damage. Any vessels in the brain or spinal cord can be involved . SS-associated systemic vasculitic manifestations occur in approximately 5–10% of SS patients  and two histopathological types have been suggested according to the type of the infiltrating cell: the neutrophilic type and the mononuclear cell type . In SS-associated vasculitis, there is direct vessel wall invasion by neutrophilic or mononuclear cells, hyperplasia of endothelial and smooth muscle cells, and immune complex deposits. These pathological factors alter or destroy the normal structure of the vessel wall, and result in vessel lumen occlusion, or wall rupture due to changes in local pressure at a weak point in the vessel wall . Abnormal collateral vessels (moyamoya vessels) at the base of the brain may develop in autoimmune diseases such as SS [8, 15]. In such conditions, the abnormal vascular network is termed quasi-moyamoya disease . Moyamoya vessels are prone to thrombosis or hemorrhage due to fibrin deposits in their walls, fragmented elastic laminae, attenuated media, and microaneurysm formation . It is well known that hemorrhagic stroke from moyamoya vessels occurs predominantly in adult moyamoya disease patients. If hypoperfusion is confirmed, bypass surgery may be considered to prevent rebleeding .
The most common serologic finding in SS is hypergammaglobulinemia, which is found in 80% of pSS patients . The elevated immunoglobulin levels in SS patients contain a number of autoantibodies, including rheumatoid factors, and antinuclear, anti-SS-A and anti-SS-B antibodies . The presence of these autoantibodies is closely related to the occurrence of vasculitis .
The non-specific and diverse nature of pSS leads to an average diagnostic delay of 3–8 years [19, 20], even though 100% of pSS patients have exocrine gland involvement. Patients presenting with sicca symptoms account for fewer than half of all pSS patients .
Our patient’s sicca symptoms were not obvious clinically either before or after hemorrhage. Currently, the diagnosis of pSS is based on the following: high titers for anti-SS-A/Ro, SS-B/La, and recombinant Ro-52 antibodies and rheumatoid factor; elevated IgG and IgA; accelerated ESR; decreased exocrine glandular function; no trace of other autoimmune or infectious disease; and the revised classification criteria for Sjögren’s syndrome proposed by the American-European Consensus Group . We hypothesized that in our patient, the pSS-associated vasculitis might have contributed to the development of the asymptomatic occlusion of the left terminal portion of the internal carotid artery and the subsequent development of moyamoya vessels, ICH, and multiple lacunar infarctions.
Vasculitis-associated clues should be carefully investigated in adult female patients with stroke, particularly those without common stroke risk factors, such as hypertension or coagulopathy.
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
We wish to acknowledge Dr. Zhe Guo (Department of Nuclear Medicine, General Hospital of Beijing Military Region, China) for her technical support with radiological analyses and interpretation. We would like to thank Dr. Ru-Jing Ma (Municipal People’s Hospital, Qian’an, Hebei Province, China) and Dr. Yan-Xin Li (Department of Rheumatology and Immunology, General Hospital of Beijing, China) for their assistance in the patient’ diagnosis and treatment. This work was supported by grant from the National Natural Science Foundation of China (No. 81070948).
- Plesivcnik Novljan M, Rozman B, Hocevar A, Grmek M, Kveder T, Tomsic M: Incidence of primary Sjogren’s syndrome in Slovenia. Ann Rheum Dis. 2004, 63: 874-876. 10.1136/ard.2003.014027.View ArticlePubMedGoogle Scholar
- Weng MY, Huang YT, Liu MF, Lu TH: Incidence and mortality of treated primary Sjogren’s syndrome in Taiwan: a population-based study. J Rheumatol. 2011, 38: 706-708. 10.3899/jrheum.100883.View ArticlePubMedGoogle Scholar
- Goëb V, Salle V, Duhaut P, Jouen F, Smail A, Ducroix JP, Tron F, Le Loët X, Vittecoq O: Clinical significance of autoantibodies recognizing Sjögren’s syndrome A (SS-A), SSB, calpastatin and alpha-fodrin in primary Sjögren’s syndrome. Clin Exp Immunol. 2007, 148: 281-287. 10.1111/j.1365-2249.2007.03337.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Massara A, Bonazza S, Castellino G, Caniatti L, Trotta F, Borrelli M, Feggi L, Govoni M: Central nervous system involvement in Sjögren’s syndrome: unusual, but not unremarkable clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology (Oxford). 2010, 49: 1540-1549. 10.1093/rheumatology/keq111.View ArticleGoogle Scholar
- Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, Dubucquoi S, Pruvo JP, Vermersch P, Hatron PY: Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore). 2004, 83: 280-291. 10.1097/01.md.0000141099.53742.16.View ArticleGoogle Scholar
- Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, Katsuno M, Fujita A, Aiba I, Ogata A, Saito T, Asakura K, Yoshida M, Hirayama M, Sobue G: The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain. 2005, 128: 2518-2534. 10.1093/brain/awh605.View ArticlePubMedGoogle Scholar
- Fauchais AL, Magy L, Vidal E: Central and peripheral neurological complications of primary Sjögren’s syndrome. Presse Med. 2012, 41: e485-e493. 10.1016/j.lpm.2012.06.002.View ArticlePubMedGoogle Scholar
- Asai Y, Nakayasu H, Fusayasu E, Nakashima K: Moyamoya Disease Presenting as Thalamic Hemorrhage in A Patient With Neuromyelitis Optica and Sjögren’s Syndrome. J Stroke Cerebrovasc Dis. 2012, 21: 619. e7-9.View ArticlePubMedGoogle Scholar
- Ishizaka S, Hayashi K, Otsuka M, Fukuda S, Tsunoda K, Ushijima R, Kitagawa N, Suyama K, Nagata I: Syringomyelia and arachnoid cysts associated with spinal arachnoiditis following subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 2012, 52: 686-690. 10.2176/nmc.52.686.View ArticleGoogle Scholar
- Hayashi K, Morofuji Y, Suyama K, Nagata I: Recurrence of subarachnoid hemorrhage due to the rupture of cerebral aneurysms in a patient with Sjögren’s syndrome: case report. Neurol Med Chir (Tokyo). 2010, 50: 658-661. 10.2176/nmc.50.658.View ArticleGoogle Scholar
- Klingler JH, Gläsker S, Shah MJ, Van Velthoven V: Rupture of a spinal artery aneurysm attributable to exacerbated Sjögren syndrome: case report. Neurosurgery. 2009, 64: e1010-e1011. 10.1227/01.NEU.0000344002.21699.A3.View ArticlePubMedGoogle Scholar
- Giordano MJ, Commins D, Silbergeld DL: Sjögren’s cerebritis complicated by subarachnoid hemorrhage and bilateral superior cerebellar artery occlusion: case report. Surg Neurol. 1995, 43: 48-51. 10.1016/0090-3019(95)80037-H.View ArticlePubMedGoogle Scholar
- Feist E, Hermann KG, Dankof A: Vasculopathy in Sjögren’s syndrome. Z Rheumatol. 2009, 68: 305-311. 10.1007/s00393-008-0400-8.View ArticlePubMedGoogle Scholar
- Molina R, Provost TT, Alexander EL: Two types of inflammatory vascular disease in Sjögren’s syndrome. Differential association with seroreactivity to rheumatoid factor and antibodies to Ro (SS-A) and with hypocomplementemia. Arthritis Rheum. 1985, 28: 1251-1258. 10.1002/art.1780281109.View ArticlePubMedGoogle Scholar
- Yanagawa Y, Sugiura T, Suzuki K, Okada Y: Moyamoya disease associated with positive findings for rheumatoid factor and myeloperoxidase-anti-neutrophil cytoplasmic antibody. West Indian Med J. 2007, 56: 282-284.View ArticlePubMedGoogle Scholar
- Hayashi K, Horie N, Suyama K, Nagata I: An epidemiological survey of moyamoya disease, unilateral moyamoya disease and quasi-moyamoya disease in Japan. Clin Neurol Neurosurg. 2013, 115: 930-933. 10.1016/j.clineuro.2012.09.020.View ArticlePubMedGoogle Scholar
- Yamashita M, Oka K, Tanaka K: Histopathology of the brain vascular network in moyamoya disease. Stroke. 1983, 14: 50-58. 10.1161/01.STR.14.1.50.View ArticlePubMedGoogle Scholar
- Kassan SS, Moutsopoulos HM: Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med. 2004, 164: 1275-1284. 10.1001/archinte.164.12.1275.View ArticlePubMedGoogle Scholar
- Pavlidis NA, Karsh J, Moutsopoulos HM: The clinical picture of primary Sjögren’s syndrome: a retrospective study. J Rheumatol. 1982, 9: 685-690.PubMedGoogle Scholar
- Markusse HM, Oudkerk M, Vroom TM, Breedveld FC: Primary Sjögren’s syndrome: clinical spectrum and mode of presentation based on an analysis of 50 patients selected from a department of rheumatology. Neth J Med. 1992, 40: 125-134.PubMedGoogle Scholar
- Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren’s Syndrome: Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002, 61: 554-558. 10.1136/ard.61.6.554.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/13/100/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.